Should You Jump Into the Alumis Stock Rally Now?

Alumis (ALMS) Shares Surge Following Positive Phase 3 Results

Alumis (ALMS) stock soared on Tuesday after the company announced encouraging Phase 3 trial outcomes for envudeucitinib, its investigational oral therapy for psoriasis.

According to the company’s statement, patients in the advanced-stage study experienced symptom relief that stands out among oral treatments for the condition.

Related Updates from Barchart

Although ALMS shares gave back nearly half of their intraday gains by the close on January 6, they reached a peak of $22.30 during the session.

Is Alumis a Buy After Envudeucitinib’s Breakthrough?

The latest Phase 3 data marks a turning point for Alumis, as envudeucitinib achieved all major and secondary goals, showing better skin clearance than current therapies.

This success positions ALMS as a formidable player in the lucrative psoriasis market, which is currently led by giants like Bristol Myers (BMY) and Johnson & Johnson (JNJ).

Notably, the treatment demonstrated rapid effectiveness, with significant improvements observed as early as the fourth week, highlighting its potential to set new standards in care.

Should the drug receive regulatory approval, Alumis could establish itself in one of the largest immunology sectors, shifting from a speculative biotech to a promising growth story.

What Do Options Trends Reveal About ALMS’s Future?

Despite closing well below its intraday high on January 6—suggesting much of the surge was driven by sentiment—there are compelling reasons to consider ALMS for long-term investment.

The global psoriasis market is valued in the tens of billions annually, so even a small share could result in substantial gains for Alumis.

Additionally, the company’s pipeline features other immunology candidates, providing opportunities beyond psoriasis.

In summary, Alumis offers investors early access to several advanced therapeutic markets, at a time when optimism for biotech is expected to rise in 2026.

Data from Barchart indicates that bullish options expiring in mid-April point to a possible 15% increase, suggesting ALMS could approach $19 within the next four months.

Wall Street’s Take on Alumis

Analysts on Wall Street recommend holding onto Alumis shares, especially given the company’s recent fundraising efforts, which should support commercialization plans in 2026.

The consensus rating for ALMS is currently “Strong Buy,” with an average price target near $20—implying over 20% potential upside from current levels.